Active, not recruitingPhase 3NCT06106828
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Studying Developmental defect of the eye
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Satralizumab(drug)
- Enrollment
- 127 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Plastics-Orbit-Neuro, San Diego, California, United States
- Connecticut Eye Consultants, P.C., Danbury, Connecticut, United States
- University of Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
- Scheie Eye Institute, Philadelphia, Pennsylvania, United States
- Vanderbilt Eye Institute, Nashville, Tennessee, United States
- Retina Consultants of Texas, San Antonio, Texas, United States
- University of Alberta, Edmonton, Alberta, Canada
- Toronto Retina Institute, Toronto, Ontario, Canada
- Universite de Montreal - Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
- Peking Union Medical College Hospital, Beijing, China
- Peking University Third Hospital, Beijing, China
- Beijing Hospital of Ministry of Health, Beijing, China
- Beijing Tongren Hospital, Capital Medical University, Beijing, China
- Xi'an Fourth Hospital, Xi'an, China
- CHU Nantes - Hotel Dieu, Nantes, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06106828 on ClinicalTrials.govOther trials for Developmental defect of the eye
Additional recruiting or active studies for the same condition.